Sector News

Nestle, Stada prepare rival bids for Germany's Merck consumer health: sources

December 4, 2017
Life sciences

Swiss food giant Nestle and the private equity owners of German drug firm Stada are both preparing tentative bids for Merck KgaA’s consumer health unit, several sources told Reuters.

Merck’s financial adviser JPMorgan has invited bids for the business, which is valued at about 4 billion euros ($4.8 billion), ahead of a Dec. 15 deadline, the sources said.

Nestle is widely seen as a natural buyer for the maker of Seven Seas vitamins and Bion nutritional supplements, after previous talks to set up a consumer joint venture with Merck fell through over the summer.

Bain and Cinven, who earlier this year took control of Germany’s Stada, are hoping to use the Merck unit as a buy-and-build platform for Stada, which makes generic drugs and consumer care products and had annual revenues of more than 2 billion euros in 2016, the sources said.

The private equity firms are making an opportunistic move on Merck consumer health as they want to have options to build on the business they have with Stada, one of the sources said.

Other buyout funds which do not have a presence in the consumer and healthcare industries and would not be able to use existing portfolio companies as an acquisition vehicle have been advised against entering the process, they said.

Merck, which declined to comment, has seen enough interest from industry buyers, they said, pointing to takeover appetite from emerging markets.

Nestle, Stada, Cinven and Bain all declined to comment.

Merck’s vitamins and nutritional supplements would fit Nestle’s ambition to expand in consumer healthcare, a fast-growing area CEO Mark Schneider has made a priority.

Nestle has also been offered the $20 billion consumer health business that U.S. drug giant Pfizer is selling, the sources said.

But Merck’s portfolio is smaller and less diversified than Pfizer’s and would keep Nestle closer to its core strength in packaged food, the sources said.

Nestle, which wants to become a “nutrition, health and wellness company,” promised shareholders in September that moving into consumer health would not be “a carte blanche for reckless diversification.”

Consumer health is a fragmented sector ranging from over-the-counter medicines and vitamins to sports nutrition products and condoms. It has proved fertile ground for deals in recent years, as aging populations and health-conscious consumers drive demand.

Stada’s owners are also mulling bids for the generic drug business being sold by Sanofi, the sources said, and might favor this combination over Merck as generic drugs are typically valued at a cheaper multiple.

Merck said in September that it would consider selling the $1 billion-a-year consumer health unit to help fund more research into prescription drugs.

($1 = 0.8401 euros)

By Pamela Barbaglia, Ludwig Burger, Patricia Weiss

Source: Reuters

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend